Cagrisema Sodium

Peptide Compound for Metabolic ResearchResearch use only

Half-life

5–7 days (approximate)

Delivery

Subcutaneous injection

Dosage

—

Research Use Only

All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.

Purchase

No purchase links available

Description

Cagrisema is a co-formulation of cagrilintide and semaglutide, combining the effects of amylin and GLP-1 receptor agonism for enhanced weight loss and glycemic control.

Usage

Used in research on obesity, appetite regulation, and glucose metabolism. Promising results in weight loss and Type 2 diabetes models.

Mechanism of Action

Combines GLP-1 receptor activation with amylin receptor activity to suppress appetite, slow gastric emptying, and improve metabolic parameters.

Benefits(4)

Appetite suppression
Weight reduction
Improved glucose control
Delayed gastric emptying

Side Effects(4)

Nausea
Constipation
Loss of appetite
Mild gastrointestinal discomfort